期刊名称：EXPERT REVIEW OF MEDICAL DEVICES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims & Scope
Expert Review of Medical Devices (ISSN 1743-4440) provides commentary, analysis and debate for all professionals involved in research, development, testing and clinical use of devices.
The journal serves the device research community by providing a comprehensive body of high-quality information from leading experts, all subject to rigorous peer-review. The Expert Review format is specially structured to optimize the value of the information to reader. Comprehensive coverage by each author in a key area of research or clinical practice is augmented by the following sections:
- Expert Commentary - the author's personal assessment of the most promising therapies or strategies
- Five-year view - the author is challenged to predict how the particular field will evolve in the medium term
- Key issues - an executive summary of the author's most important points and conclusions
In addition to the Review program, each issue also features Medical Device Profiles - objective assessments of specific devices in development or clinical use to help inform clinical practice. There are also Perspectives - overviews highlighting areas of current debate and controversy, together with reports from the conference scene and invited Editorials.
Instructions to Authors
EXPERT REVIEW OF MEDICAL DEExpert Review series Author Guidelines
Contents
Audience
Commissioning policy
Article types
Reviews
Perspectives
Special reports
Editorials
Key paper evaluations
Meeting Reports
Key formatting points
Manuscript preparation
Spacing & headings
Spelling
Abbreviations
References
Format
Examples
Reference annotations
Figures/Tables/Boxes
Color printing charge
Chemical structures
Electronic figure files
Copyright
Submission
Peer review
R
evision
Conflicts of interest policy
Financial disclosure
Author disclosure form
Future Drugs is part of the Future Science Group, an expanding group of independent companies active in the field of scientific information and endeavor
Audience
The audience for the Expert Review series of journals consists of clinicians, research scientists, decision-makers and a range of professionals in the healthcare community. Authors should bear in mind the multidisciplinary status of the readership when writing the article.
Commissioning policy
We accept unsolicited manuscripts for publication in all Future Drugs journals. If you are interested in submitting an article, please contact the Commissioning Editor of the relevant journal with a brief proposal and article outline in the first instance.
We also have an active commissioning program whereby the Commissioning Editor, under the advice of the Editorial Advisory Board, solicits articles for publication by Future Drugs.
Article types
Reviews
Word limit: 7000 words (excluding Abstract, Key issues, References and Figure/Table legends)
Required sections: Abstract, Keywords, Expert Commentary, Five-year view, Key issues, References, Reference Annotations
These articles aim to summarize current therapeutic practice, highlighting recent significant advances and ongoing challenges and unmet needs. An evaluation of the pharmacoeconomic situation is recommended where relevant. The final structure of the review will, of course, depend on the title/focus.
Perspectives
Word limit: 3000 words (excluding Abstract, Key Issues, References and Figure/Table legends)
Required sections: Abstract, Keywords, Expert Commentary, Five-year view, Key issues, References, Reference Annotations
These articles have the same basic structure and length as review articles, however they should be more speculative and very forward looking, even visionary. They offer the author the opportunity to present criticism or address controversy. Authors of perspectives are encouraged to be highly opinionated. The intention is very much that these articles should represent a personal perspective. Referees will be briefed to review these articles for quality and relevance of argument only. They will not necessarily be expected to agree with the authors?sentiments.
Special Reports
Word limit: 1500?000 words (excluding Abstract, Key Issues, References and Figure/Table legends)
Required sections: Abstract, Keywords, Expert Commentary, Five-year view, Key issues, References, Reference Annotations
These articles are short review-style articles that summarize a particular niche area, be it a specific technique or therapeutic method, particularly focusing on the authors personal experience in this area.
Editorials
Word limit: 1000?500 words
Required sections: Photo (headshot) of authors (Please try to avoid the use of figures and tables in editorials)
These are short articles on issues of topical importance. We encourage our editorial writers to express their opinions, giving the author the opportunity to present criticism or address controversy. The intention is very much that the article should offer a personal perspective on a topic of recent interest.
Key paper evaluations
Word limit: 1500 words
Required sections: Abstract, Keywords, Expert Commentary, Five-year view, Key issues, References, Reference Annotations (NB. The paper being evaluated should be listed in the bibliography as reference 1)
These articles review significant, recently published primary research articles carefully selected and assessed by specialists in the field. The primary research detailed in the chosen paper is discussed with the aim of keeping readers informed of the most promising discoveries/breakthroughs relevant to the subject of the journal through review and comment from experts.
Key Paper Evaluations are intended to extend and expand on the information presented, putting it in context and explaining why it is of importance.
The ideal article will provide both a critical evaluation and the author抯 opinion on the quality and novelty of the information disclosed.
Meeting Reports
Word limit: 1500 words
Required sections: Please provide the name, date and location of the conference being reported
These articles aim to summarize the most important research presented at a recent conference in the subject area of the journal.
It is not usually feasible to attempt comprehensive coverage of the conference, as presentations are frequently too numerous for each to be done justice. The author should focus on those presentations that are most topical, interesting or thought-provoking.
Key formatting points
Please ensure your paper concurs with the following article format:
Title: concise, not more than 120 characters.
Author(s) names & affiliations: including full name, address, phone & fax numbers and e-mail.
Abstract/Summary: approximately 120 words.
Keywords: approximately 5?0 keywords for the review.
Body of the article
Expert commentary: expert analysis of the data presented in the review.
Five-year view: a speculative viewpoint on how the field will evolve in 5?0 years time.
Key issues: an executive summary of the authors?main points (bulleted) is very useful for time-constrained readers requiring a rapidly accessible overview.
References:
?Should be numerically listed in the reference section in the order that they occur in the text. References should appear as a number i.e., [1,2] in the text.
?If websites or patents are included, please use a separate numbering system, i.e., start numbering website references at [101] and patents at [201] to allow the reader to distinguish between websites/patents and primary literature references both in the text and in the bibliography.
?Any references that are cited in figures/tables/boxes that do not appear in the text should be listed at the end of the reference list in the order they occur.
Reference annotations: please highlight 6? references that are of particular significance to the subject under review as ? of interest?or ?* of considerable interest?and provide a brief (1? line) synopsis.
Figures/Tables/Boxes: Summary figures/tables/boxes are very useful, and we encourage their use in reviews/perspectives/special reports. The author should include illustrations and tables to condense and illustrate the information they wish to convey. Commentary that augments an article and could be viewed as 憇tand-alone?should be included in a separate box. An example would be a summary of a particular trial or trial series, a case study summary or a series of terms explained.
If any of the figures used in the manuscript require permission from the original publisher, it is the author抯 responsibility to obtain this. Figures must be in an editable format.
For information regarding colour figures, please see the section below
Manuscript preparation
Spacing & headings
Please use double line spacing throughout the manuscript. No more than four levels of subheading should be used to divide the text and should be clearly designated.
Abbreviations
Abbreviations should be defined on their first appearance, and in any table and figure footnotes. A separate list of abbreviations is useful to our production department but not a strict requirement.
Spelling
US-preferred spelling will be used in the finished publication.
References
Authors should focus on recent papers and papers older than 5 years should not be included except for an over-riding purpose.
References should be denoted numerically and in sequence in the text, using Arabic numerals placed in square brackets, i.e., [12].
If websites or patents are included, please use a separate numbering system for them, i.e., start numbering website references at [101] and patents at [201] to allow the reader to distinguish between websites/patents and primary literature references both in the text and in the bibliography.
The Future Drugs EndNote style for references is available to download from the Future Drugs website (compatible with Mac EndNote 9).
Format
?Author抯 names should appear without full stops in their initials
?Quote first six authors?names. If there are more than six, then quote first three et al.
?A full stop follows the last authors?name.
?Journal name should be in italics and abbreviated to standard format
?Volume number followed by comma, not bold
?Page number range separated by a hyphen with no spaces, followed by the year in brackets, and then a full stop
Examples
Journal example:
Fantl JA, Cardozo L, McClish DK et al. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. Obstet. Gynecol. 83(1), 12?8 (1994).
Book example:
De Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In: The Autonomic Nervous System (Volume 6). Andrews WR (Ed.), Harwood Academic Publishers, London, UK, 227?89 (1993).
Meeting abstract example:
Smith AB, Jones CD. Recent progress in the pharmacotherapy of diseases of the lower urinary tract. Presented at: 13th International Symposium on Medicinal Chemistry. Atlanta, GA, USA, 28 November? December 1994.
Patent example:
Merck Frosst Canada, Inc. WO9714691 (1997).
(Use the following formats for patent numbers issued by the World, US and European patent offices, respectively: WO1234567, US1234567, EP-123456-A).
Reference annotations
Papers or of particular interest should be identified using one or two asterisk symbols:
?= of interest
?** = of considerable interest
Each of the chosen references should be annotated with a brief sentence explaining why the reference is considered to be of interest/particular interest.
Figures/Tables/Boxes
Figures/Tables/Boxes should be numbered consecutively according to the order in which they have been first cited in the text. Define in the legend all abbreviations that are used in the figure.
Figures/Tables/Boxes should be provided in separate files to the text. It is unnecessary to incorporate the figures into the body of the manuscript.
Color figure charge
The final print-only copy of the journal will be printed in black and white. Should an author wish to have colour figures in the complimentary hard copy of the journal, there is a small charge (calculated per color page required). We aim to keep our color charge to a minimum and we are happy to work with authors to come to a suitable arrangement.
This charge does not apply to the online (including PDF) version of articles, where all figures appear in color at no charge.
Chemical structures
If possible, please submit structures drawn in ISIS/Draw or ChemDraw format. However, chemical structures can be redrawn in-house. Please use the following conventions:
?Always indicate stereochemistry where necessary ?use the wedge and hash bond convention for chiral centers and mark cis/trans bonds as such
?Draw small peptides (up to five amino acids) in full; use amino acid abbreviations (Gly, Val, Leu, etc.) for larger peptides
?Refer to each structure with a number in the text; submit a separate file (i.e., not pasted throughout the text) containing these numbered structures in the original chemical drawing package that you used and as a hard copy.
Electronic figure files
Please submit any other illustrations/schemes in an electronic format such as Illustrator, CorelDraw, PowerPoint, Excel or as PC-compatible postscripted/encapsulated postscripted (.ps/.eps) files. Otherwise, please ensure camera-ready copy is of high resolution.
Copyright
If a figure has been published previously (even if you were the author), acknowledge the original source and submit written permission from the copyright holder to reproduce the material.
As the author of your manuscript, you are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be remarkably time-consuming, it is wise to begin writing for permission as soon as possible. Please send us photocopies of letters or forms granting you permission for the use of copyrighted material so that we can see that any special requirements with regard to wording and placement of credits are fulfilled. Keep the originals for your files. If payment is required for use of the figure, this should be covered by the author.
Submission
Please ensure that manuscripts are submitted on or before the agreed deadline. If a manuscript requires authorization by your organization before submission, please remember to take this into account when working towards these deadlines.
If possible, please submit manuscripts in MS Word v. 6? and above. However, we can convert most word-processing packages. Submission should be made by e-mail in the first instance.
Peer review
Once the manuscript has been received in-house, it will be peer-reviewed (this usually takes 2? weeks). Please provide a list of suitable peer reviewers with your initial submission.
Revision
After peer review is complete, a further 2 weeks is allowed for any revisions (suggested by the referee/Editor) to be made.
Conflicts of interest policy
It is the responsibility of the author(s) to disclose any affiliation with any organization with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, expert testimony, honoraria, speakers' bureaus, retainers, stock options or ownership) that may affect the conduct or reporting of the work submitted. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure.
Authors will be asked to certify that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under my authorship has been published or is being considered for publication elsewhere, except as described in an attachment, and copies of closely related manuscripts are provided.
External peer reviewers must disclose any conflicts of interest that could bias their opinions of the manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe it appropriate. Should any such conflict of interest be declared, the journal Editor will judge whether the reviewer's comments should be recognized or will interpret the reviewer's comments in the context of any such declaration.
Details of relevant conflicts of interests (or the lack of) must be declared in the 'Disclosure' section of the manuscript for all listed authors.
Future Drugs expects manuscripts to conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (the Vancouver style; N. Engl. J. Med. 336, 309?15 [1997] or www.icmje.org).
Financial disclosure
Authors are required to declare any financial interests relating to their manuscript or to confirm that they have no such interest.
Authors must certify that all financial and material support for the research and work are clearly identified in the manuscript.
Authors must certify that all affiliations with or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in their manuscript have been disclosed.
Please note examples of financial involvement include: employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending and royalties. This is list is not exclusive of other forms of financial involvement.
Author disclosure form
The form at the end of this document should be completed by the authors and submitted with the 1st draft of the article.
Contact Details
Please contact the Commissioning Editor for the relevant journal in the first instance.
For general queries regarding Future Drugs titles, please contact the Senior Editors: Kelly McCauley or Morag RoberstonVICES
Editorial Board
Editorial StaffSenior Editors: Kelly McCauley
Morag Robertson
Managing Editor: Morag Robertson
Commissioning Editor: Elizabeth Poll
Assistant Commissioning Editor: Zoe Richmond
Managing Production Editor: Lian Evans
Production Editor: Rupert Gilley
Assistant Production Editors: Hannah Marr
Philip Chapman
Madalina Black
|
刊名字顺( Alphabetical List of Journals):
返回页首 